research Retrospective Analysis of Pediatric Alopecia Areata Treated with Methotrexate
Methotrexate may effectively and safely treat hair loss in children, with notable improvement after 12-15 months.
Search
for
Sort by
Research
210-240 / 1000+ results research Objective and Subjective Assessments of the Response of Photobiomodulation Therapy Against Alopecia Areata
Photobiomodulation therapy effectively promotes hair regrowth and improves quality of life in alopecia areata without side effects.
research Intralesional Methotrexate versus Triamcinolone Acetonide for Localized Alopecia Areata (AA) Treatment
Both treatments improved alopecia areata, but methotrexate caused more skin darkening, while triamcinolone caused skin lightening and thinning.
research High frequency of cutaneous manifestations including vitiligo and alopecia areata in a prospective cohort of patients with chronic graft-vs-host disease
Patients with chronic graft-versus-host disease often have skin problems like vitiligo and alopecia areata.
research How Long to Treat to Achieve Desired Treatment Outcomes with Baricitinib 4 mg in Severe Alopecia Areata: Evidence-based Approach
The study investigates the effectiveness of baricitinib 4 mg in treating severe alopecia areata (AA) by analyzing the time required to achieve significant hair regrowth. In a post hoc analysis of the BRAVE-AA1/2 trials, patients were categorized based on baseline disease severity and episode duration. Results showed that in severe AA cases (SALT score 50–94), 70% with short duration and 61% with long duration achieved initial improvement (SALT30) by Week 24, with 75% and 65% reaching treatment success (SALT score ≤ 20) by Week 52. In very severe AA cases (SALT score 95–100), 42% with short duration and 25% with long duration achieved SALT30 by Week 24, leading to 58% and 43% achieving treatment success by Week 52. The findings suggest that treatment should continue for at least 1 year before determining failure, especially in very severe cases.
research Evidence-Based Data on How Long to Treat to Achieve Treatment Response With Baricitinib in Severe Alopecia Areata
Baricitinib treatment for severe alopecia areata shows significant improvement by 52 weeks, especially in very severe cases.
research Comparative Efficacy Evaluation of Alopecia Areata Management with Janus Kinase Inhibitors in Children: Retrospective Cohort Study
Tofacitinib is more effective than traditional treatments for severe alopecia areata in children.
research Scalp hair cortisol concentration in patients with alopecia areata and correlate its level with the disease variables
Higher stress levels may worsen alopecia areata, suggesting stress management is important for treatment.
research Evaluation of the Efficacy of Antihistamines in the combined therapy for Alopecia Areata
Combining antihistamines with topical treatment improves hair regrowth in alopecia areata.
research Alopecia areata: An update
The document concludes that alopecia areata is an autoimmune disease without a definitive cure, but treatments like corticosteroids are commonly used.
research Platelet-Rich Plasma for Androgenetic Alopecia in Women: A Single-Center Case Series Study in Qatar
PRP is an effective and safe treatment for hair loss in women.
research Evaluation of platelet-rich plasma on hair regrowth and lesional T-cell cytokine expression in alopecia areata: A randomized observer-blinded, placebo-controlled, split-head pilot study
Platelet-rich plasma may help restore immune balance in bald patches, but its effectiveness in treating hair loss is limited.
research Nemolizumab Treatment for Severe Atopic Dermatitis Led to the Simultaneous Improvement of Coexisting Refractory Alopecia Areata: A Case Report
Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.
research Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients
Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
research Cyclosporine for moderate-to-severe alopecia areata: A double-blind, randomized, placebo-controlled clinical trial of efficacy and safety
Cyclosporine showed some improvement in alopecia areata but results were not statistically significant.
research Bilateral Half-Head Comparison of 1% Anthralin Ointment in Children with Alopecia Areata
1% anthralin ointment is effective and safe for treating severe alopecia areata in children.
research Low-Dose IL-2 for Treating Moderate to Severe Alopecia Areata: A 52-Week Multicenter Prospective Placebo-Controlled Study Assessing its Impact on T Regulatory Cell and NK Cell Populations
The study's results on the effectiveness of low-dose IL-2 for alopecia areata and its impact on immune cells were not provided.
research Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)
Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
research Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study
Dupilumab helps children with alopecia areata regrow hair safely.
research Efficacy of Postbiotics in a PRP-Like Cosmetic Product for the Treatment of Alopecia Area Celsi: A Randomized Double-Blinded Parallel-Group Study
The PRP-like cosmetic product with postbiotics effectively treats hair loss in Alopecia areata.
research Serum level of vitamin D in patients with alopecia areata
Alopecia areata patients have lower vitamin D levels than healthy individuals.
research Trichoscopy as an evaluation method for alopecia areata treatment: A comparative study
Trichoscopy is useful for diagnosing and monitoring alopecia areata treatment.
research Evaluation of association of vitamin D in alopecia areata: A case–control study of 100 patients in a tertiary rural hospital of Southern India
People with alopecia areata often have lower vitamin D levels, which may be linked to the condition's severity.
research Baricitinib for the Treatment of Alopecia Areata
Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
research Dupilumab for the treatment of alopecia areata in pediatric patients with atopic dermatitis: A scoping review
Dupilumab effectively reduces alopecia areata symptoms in children with atopic dermatitis.
research Real-world assessment of ritlecitinib in patients with severe alopecia areata: a 24-week multicentre retrospective study
Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
research Evaluation of fractional carbon dioxide laser alone versus its combination with betamethasone valerate in treatment of alopecia areata, a clinical and dermoscopic study
The fractional carbon dioxide laser is a safe and effective treatment for alopecia areata and works better than betamethasone valerate cream alone.
research 34007 Efficacy and safety of baricitinib in adult patients with severe alopecia areata with or without an atopic background from 2 randomized, placebo-controlled, phase 3 trials
Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.
research Time to loss of response for dupilumab in ophiasis-pattern alopecia areata
Dupilumab helped a woman with severe hair loss regrow her hair quickly and maintain it for six months after stopping treatment.
research The effect of latanoprost 0.005% solution in the management of scalp alopecia areata, a randomized double‐blind placebo‐controlled trial
Latanoprost 0.005% solution safely increases hair density and regrowth in scalp alopecia areata.